Zenlabs Ethica Limited (BOM:530697)

India flag India · Delayed Price · Currency is INR
19.75
-0.49 (-2.42%)
At close: Jan 21, 2026
-44.07%
Market Cap126.29M
Revenue (ttm)496.19M
Net Income (ttm)2.47M
Shares Out6.51M
EPS (ttm)0.38
PE Ratio50.77
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,851
Average Volume3,446
Open19.25
Previous Close20.24
Day's Range19.15 - 20.14
52-Week Range18.50 - 39.49
Beta-1.11
RSI39.17
Earnings DateNov 8, 2025

About Zenlabs Ethica

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries
Founded 1993
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 530697
Full Company Profile

Financial Performance

In 2024, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.

Financial Statements